Abstract
Aims: Psoriasis is an inflammatory skin disease with several comorbidities. We aimed to evaluate red blood cell distribution width (RDW), platelet parameters and inflammatory markers in patients on antipsoriasis therapies.
 Methods: 94 psoriasis patients and 74 healthy controls were prospectively analyzed. Before and after 8 weeks of different therapies (calcipotriol+clobetasol propionate; narrow-band UVB; combined narrow-band UVB and acitretin; infliximab and adalimumab), red blood cell distribution width (RDW), platelet parameters, high sensitivity C reactive protein (hs-CRP), and erythrocyte sedimentation rate (ESR) levels were measured. Lipid profile and fasting blood glucose tests were also performed prior the treatment. Psoriasis severity and area index (PASI) and body mass index (BMI) were calculated for each patient.
 Results: RDW, hs-CRP, triglyceride, total cholesterol levels and BMI were higher in patients than in controls (p<0.05, for all four). No significant differences were observed in RDW, platelet parameters, hs-CRP and ESR levels after all therapies (p>0.05, for all). RDW was not correlated with PASI (p>0.05).
 Conclusion: Psoriasis patients should be screened for dyslipidemia and obesity. Antipsoriasis therapies do not have any effect on inflammatory markers. Further studies are needed to elucidate the use of RDW and platelet parameters as an inflammatory marker in psoriasis.
Highlights
Psoriasis which is a chronic, recurrent skin disease is characterized by systemic inflammation leading to certain autoinflammatory diseases including cardiovascular disease, obesity, insulin resistance, and thromboembolic events [1]
Mean Red blood cell distribution width (RDW), mean platelet volume (MPV), platelet volume distribution width (PDW), PCT, Hb, erythrocyte sedimentation rate (ESR), high sensitivity C reactive protein (hs-CRP), total cholesterol, LDL, TG, fasting blood glucose (FBG) levels were higher in the patients than in the controls but the differences were statistically significant only for RDW, hs-CRP, TG and total cholesterol (p=0.020, p=0.049, p=0.005, p=0.049)
Kim et al [35] conducted a retpathogenesis of psoriasis, T cell-mediated inflam- rospective study on 261 psoriasis patients and 102 mation involving Th1/Th2 homeostasis, the Th17/ healthy controls and they found that the mean RDW
Summary
Psoriasis which is a chronic, recurrent skin disease is characterized by systemic inflammation leading to certain autoinflammatory diseases including cardiovascular disease, obesity, insulin resistance, and thromboembolic events [1]. There are many parameters which are elevated in inflammatory diseases and they are accepted as predictors of risk for development of them [2,3]. The hemogram parameters in routine blood panels have been proposed as one of these markers in systemic inflammation [4]. Red blood cell distribution width (RDW) which is used to differentiate causes of anemia, has been reported to be related with chronic inflammation and has been defined as a prognostic tool in different clinical settings such as pulmonary arterial hypertension, congestive heart failure and coronary heart disease. We aimed to determine if RDW might be a new inflammatory marker which shows the severity of psoriasis
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have